Sarah A. Holstein

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach et al. · Blood · 2020 · 690 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Shaji Kumar, Natalie S. Callander, Melissa Alsina et al. · Journal of the National Comprehensive Cancer Network · 2017 · 280 citations · Full text

Medicine, Hematology, Oncology +17

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018

Shaji Kumar, Natalie S. Callander, Melissa Alsina et al. · Journal of the National Comprehensive Cancer Network · 2018 · 203 citations · Full text

Medicine, Hematology, Oncology +15

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

Sarah A. Holstein, Sin‐Ho Jung, Paul G. Richardson et al. · The Lancet Haematology · 2017 · 169 citations · Full text

Medicine, Hematology, Oncology +15

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

Sergio Giralt, Laurent Garderet, Brian G.M. Durie et al. · Biology of Blood and Marrow Transplantation · 2015 · 163 citations · Full text

Medicine, Hematology, Cell Therapy +15